Annals of Clinical and Experimental NeurologyAnnals of Clinical and Experimental NeurologyАнналы клинической и экспериментальной неврологии2075-54732409-2533Eco-Vector36610.17816/psaic366Original articlesОригинальные статьиUnknownStudy of the effectiveness of avonex in multiple sclerosis (1-year treatment)Исследование эффективности авонекса при рассеянном склерозе (1 год лечения)ZavalishinI. A.ЗавалишинИ. A.
Russian Federation
neuro_inf@neurology.ruPeresedovaA. V.ПереседоваA. В.
Russian Federation
neuro_inf@neurology.ruStoidaN. I.СтойдаН. И.
Russian Federation
neuro_inf@neurology.ruAskarovaLola Sh.АскароваЛола Шавкатовна
Russian Federation
neuro_inf@neurology.ruhttps://orcid.org/0000-0002-1072-99684277-2860ZakharovaMaria N.ЗахароваМария Николаевна
Russian Federation

D. Sci. (Med.), principal researcher, Head, 6th Neurological department, Institute of Clinical and Preventive Neurology

д.м.н., г.н.с., руководитель 6-го неврологического отделения Института клинической и профилактической неврологии

neuro_inf@neurology.ruAdarchevaL. S.АдарчеваЛ. С.
Russian Federation
neuro_inf@neurology.ruNiyazbekovaA. S.НиязбековаA. С.
Russian Federation
neuro_inf@neurology.ruTrifonovaOlga V.ТрифоноваОльга Васильевна
Russian Federation
neuro_inf@neurology.ruRebrovaO. Yu.РеброваO. Ю.
Russian Federation
neuro_inf@neurology.ruEliseevaD. D.ЕлисееваД. Д.
Russian Federation
neuro_inf@neurology.ruResearch Center of NeurologyФГБНУ «Научный центр неврологии»Research Center of Neurology, Russian Academy of Medical Sciences,ФГБНУ «Научный центр неврологии»Research Center of Neurology, Russian Academy of Medical SciencesФГБНУ «Научный центр неврологии»1409200933212406022017Copyright ©; 2009, Zavalishin I.A., Peresedova A.V., Stoida N.I., Askarova L.S., Zakharova M.N., Adarcheva L.S., Niyazbekova A.S., Trifonova O.V., Rebrova O.Y., Eliseeva D.D.Copyright ©; 2009, Zavalishin I.A., Peresedova A.V., Stoida N.I., Askarova L.S., Zakharova M.N., Adarcheva L.S., Niyazbekova A.S., Trifonova O.V., Rebrova O.Y., Eliseeva D.D.2009Zavalishin I.A., Peresedova A.V., Stoida N.I., Askarova L.S., Zakharova M.N., Adarcheva L.S., Niyazbekova A.S., Trifonova O.V., Rebrova O.Y., Eliseeva D.D.Zavalishin I.A., Peresedova A.V., Stoida N.I., Askarova L.S., Zakharova M.N., Adarcheva L.S., Niyazbekova A.S., Trifonova O.V., Rebrova O.Y., Eliseeva D.D.https://creativecommons.org/licenses/by/4.0https://annaly-nevrologii.com/pathID/article/view/366

In the paper, the results of 1-year treatment with avonex, a new immunomodulator from the group of interferons b, in 34 patients with relapsing remitting multiple sclerosis have been reported. In the treated patients it was shown significant decrease of the activity of the pathological process, which was evidenced by reduction of the severity of exacerbations and the relapse rate. The decrease of disability of patients with multiple sclerosis (by EDSS score) was revealed. In general, one can notice good tolerability of avonex.

В статье обобщены результаты 1 года лечения авонексом – новым иммуномодулятором из группы интерферонов – 34 больных ремиттирующим рассеянным склерозом. На фоне терапии показано достоверное уменьшение активности патологического процесса, что проявлялось снижением количества обострений и их тяжести. Выявлено уменьшение степени инвалидизации пациентов рассеянным склерозом (по шкале EDSS). В целом, данный препарат характеризовался хорошей переносимостью.

multiple sclerosistherapyavonexрассеянный склерозтерапияавонексBiernacki K., Antel J.P., Blain M. et al. Interferon beta promotes nerve growth factor secretion early in the course of multiple sclerosis. Arch. Neurol. 2005; 62: 563–568.Boutros T., Croze E., Yong V.W. Interferon-β is a potent promoter of nerve growth factor production by astrocytes. J. Neurochem. 1997; 69: 939–946.Comi G. Induction vs. escalating therapy in multiple sclerosis: practical implications. Neurol. Sci. 2008; 29 (Suppl. 2): S253–255.Farrell R., Kapoor R., Leary S. et al. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of InterferonПbeta. Mult. Sclerоsis 2008; 14: 212–218.Gneiss C., Tripp P., Reichartseder F. et al. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients. Mult. Scler. 2006; 12: 731–737.Goodin D.S., Frohman E.M., Hurwitz B. et al. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2007; 68: 977–984.Jacobs L.D., Cookfair D.L., Rudick R.A. et al. Intramuscular interferon beta-1a for disease progression in exacerbating-remitting multiple sclerosis. Ann. Neurol. 1996; 39: 285–294.Rudick R.A., Goodkin D.E., Jacobs L.D. et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Neurology 1997; 49: 358–363.Simon J.H., Jacobs L.D., Campion M. et al. Magnetic resonance studies of intramuscular interferon β-1a for relapsing multiple sclerosis. Ann. Neurol. 1996; 43: 79–87.Sorensen P.S., Deisenhammer F., Duda P. et al. Guidelines on use of anti-IFN-β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-β antibodies in multiple sclerosis. Europ. J. Neurol. 2005; 12: 817–827.Zidanov R., Locatelli L., Cookfair D. et al. Interferon beta-1a slows progression of brain atrophy in relapsing-remitting multiple sclerosis predominantly by reducing gray matter atrophy. Mult. Sclerosis 2007; 13: 490–501.Zidanov R., Munschauer F.E., Ramanathan M. et al. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon beta-1a in patients with MS and CIS. Drugs Today (Barc.) 2008; 44: 601–613.